Q-omics provides the consensus-scored MYHAS profile across patient tissues and cancer cell-line models. MYHAS expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, MYHAS is differentially expressed in 9, with the highest sampling consensus in LUAD. Additionally, MYHAS RNA expression shows 11,664 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight KICH, LUAD, and ESCA as cancer lineages where MYHAS shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MYHAS — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MYHAS survival associations across molecular data types. MYHAS RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MYHAS RNA expression–survival associations across cancer types. High MYHAS expression shows unfavorable associations in KICH, OV, ACC, COAD and LUAD, but favorable associations in UCS. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for MYHAS RNA expression.
This table summarizes MYHAS tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for MYHAS. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MYHAS shows lower tumor expression in KICH and higher tumor expression in LUAD, LUSC, LIHC, CHOL and BLCA. The LUAD box plot shows higher MYHAS RNA expression in tumor versus normal tissue (log2 FC = +0.105, t-test p < 0.001).
This table shows molecular features associated with MYHAS in patient tissues and cancer cell lines. In patient samples, MYHAS shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
